Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Anixa Biosciences, a Nasdaq-listed company, has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock buyback plan. Amit Kumar, CEO of the company, stated that the decision regarding Bitcoin is another way of prudent financial management and can achieve higher shareholder value. Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CandyBomb x RAVE: Trade futures to share 200,000 RAVE!
Bitget TradFi: Trade gold, forex, and more assets in one account
CandyBomb x US: Trade to share 5,400,000 US
[Initial Listing] Bitget to list Almanak (ALMANAK). Grab a share of 4,200,000 ALMANAK
Trending news
MoreCrypto prices
More
